AFINITOR® (everolimus) for Advanced Renal Cell Carcinoma Treatment| AFINITOR.com

AFINITOR is a once-daily oral inhibitor of mTOR (mammalian target of rapamycin) for patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with VEGF-targeted therapy

Stay informed on the latest information, including news related to AFINITOR and other updates.

Find out more about the product characteristics for AFINITOR.

Read Lancet Publication on AFINITOR Pivotal, Phase III Trial in Advanced Renal Cell Carcinoma.

^*MSKCC: Memorial Sloan-Kettering Cancer Center
References:
1. Motzer RJ, Escudier B. Oudard S, et al; for the RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet. 2008; 372:449-456.
2. AFINITOR [Summary of Product Information]. Basel, Switzerland: Novartis Pharma AG.

Disclaimer: This is an international website for AFINITOR^® (everolimus) tablets and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the left corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

NovartisOncology.com | About Novartis Oncology | Contact Us | Site Map
Use of website is governed by the Terms of Use and Privacy Policy
© 2010 Novartis AG